Beilu's Gadopentetate Dimeglumine Injection Passed the Quality and Efficacy of Generic Drugs Consistency Evaluation

Recently, our company received the “Drug Supplementary Application Approval Notice” (Notice Number: 2021B02267, 2021B02268) for two specifications of Gadopentetate Dimeglumine Injection issued by the National Medical Products Administration. This injection passed the quality and efficacy of generic drugs’ Consistency Evaluation.

Our company’s Gadopentetate Dimeglumine Injection obtained the National Class II New Drug Certificate issued by the Ministry of Health in 1992; it is mainly used for magnetic resonance imaging of human organs and tissues such as the central nervous system (brain and spinal cord), abdomen, chest, pelvis, limbs, etc. It has the advantages of a wide range of indications and high imaging quality, and the clinical use effect feedback its enhancement effect is excellent, and the side effects are few. In 2020, the company’s sales revenue of Gadopentetate Dimeglumine Injection was 184 million yuan.